ClinicalTrials.Veeva

Menu

Platelet-rich Plasma in Calcific Tendinitis

O

Orthopedisch Centrum Oost Nederland

Status

Completed

Conditions

Calcific Tendinitis

Treatments

Other: PRP
Other: Control

Study type

Interventional

Funder types

Other

Identifiers

NCT02173743
ABR 47402 (Other Identifier)
NL47402.044.13

Details and patient eligibility

About

Needle aspiration of calcific deposits (NACD ) is the treatment of choice for calcific tendinitis which does not respond to conservative treatment. NACD is effective in approximately 70% of the patients.When NACD is not effective, surgery is often the only treatment that remains.Surgery, however, is discouraged by th e Dutch guidelines for diagnosing and treating patients with subacromial pain syndrome.Therefore,both patients and the doctors treating those patients will benefit from a more effective minimal invasive treatment for calcific tendinitis.Injection of platelet-rich plasma (PRP) might, considering its positive effect on tissue repair, be a possible solution here.Previous research investigating the effects of PRP on other tendinopathies did, however, show controversial results. The aim of this double-blind randomized controlled trial is to investigate the effect of the adjuvant application of PRP after NACD on pain reduction ,recovery of shoulder function, tendon recovery,resorption of calcific deposits, the percentage of patients with persistent complaints and quality of life.

Enrollment

80 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age > 18 yrs
  • clinical manifestions of tendinitis calcarea (pain, stifness, lock sensations, muscle atrophy)
  • persistent pain sympoms >6 months
  • standardized AP x-ray shows calcific deposit of > 5mm & morphologic Type I & II deposits (classification of Gärtner en Simons)
  • ineffective intervention > 2 types of conservative treatment (among which are non-steroidal anti-inflammatory drugs, physiotherapy, local anesthesia injection and/or corticosteroids, extracorporele shock wave therapy)
  • indication and referral for barbotage by orthopeadic surgeon

Exclusion criteria

  • age > 55 years
  • morphological type III deposits according to classification of Gärtner and Simons) (as indicated by standardized x-ray AP)
  • bigliani type III acromion, and acromial spur of acromioclavicular osteovyt
  • previous (ineffective) barbotage
  • the existence of other shoulder related injuries next to calcific tendinitis (full-thickness rupture of the rotator cuff, adhesive capsulitis (frozen shoulder), arthrosis of the glenohumeral- or acromioclavicalar joint
  • shoulder joint instability
  • shoulder injury due to trauma or previous shoulder surgeries
  • other types of disorders that could negatively influence the outcomes (rheumatic arthritis. cervical spine disorders, neurological upper extremity disorders, diabetes mellitus, infections, blood disorders, malignity, pregnancy)
  • known allergic responses to one of the medications applied in the current study (lidocaine, bupivacaine, kenacort)
  • usage of anti-coagulants other than ascal of plavix

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups

PRP group
Experimental group
Description:
PRP during barbotage
Treatment:
Other: PRP
Control group
Other group
Description:
Regular barbotage
Treatment:
Other: Control

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems